Q4FY21 Result Update - Dr Reddy's Laboratories - ICICI Direct

Q4 revenues grew 7.2% YoY to Rs. 4768 crore. India sales grew 23.5% YoY to Rs. 844 crore due to Wockhardt integration and new launches. Europe revenues grew 14.8% YoY to Rs. 396 crore amid new launches. US revenues de-grew 3.2% YoY to Rs. 1749 crore mainly due to Covid related stocking in Q4FY20. Russia & Other CIS sales grew 4% to Rs. 593 crore. PSAI segment grew 10% YoY to Rs. 792 crore amid new product launches. EBITDA margins were up 75 bps YoY to 22.1% due to better product mix, partly offset by higher freight and Wockhardt integration costs. EBITDA grew 11.0% YoY to Rs. 1053 crore. PAT de-grew 28.7% YoY to Rs. 557 crore. Delta vis-a-vis EBITDA was due to negative tax outgo in base year amid DTA adjustments.

For details, click on the link below: Link to the report

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.5251.25 as compared to the previous close of Rs. 5195.85. The total number of shares traded during the day was 66143 in over 7513 trades.

The stock hit an intraday high of Rs. 5286.75 and intraday low of 5143.5. The net turnover during the day was Rs. 345116926.

Source : Equity Bulls

Keywords